Back    Zoom +    Zoom -
CN MOC Supports Qualified Biotech Firms to List on ChiNext, STAR Mkt, Beijing Stock Exchange
Recommend
35
Positive
63
Negative
27
The Ministry of Commerce (MOC) of China and the Jiangsu Provincial People's Government promulgated the “Development Plan for the Open Innovation of the Entire Biopharmaceutical Industry Chain in the China (Jiangsu) Pilot Free Trade Zone”.

The plan aims for rapid growth in the scale of the biopharmaceutical industry in the Jiangsu Free Trade Zone by 2030, with continuous optimization of the innovation ecosystem, significant enhancement of the modernization level of the industry chain, substantial improvement in the level of openness, ongoing strengthening of security capabilities, and breakthroughs in key technologies. It seeks to cultivate industry clusters with distinctive advantages in key areas such as large-molecule biologics, cell and gene therapy, and innovative medical devices.

Related NewsBOCOMI Lifts CSPC PHARMA's TP to HKD9.3 w/ Rating Kept Neutral; Valuation Reasonable
The development plan will strengthen financial support for industry development. It supports qualified biopharmaceutical innovative companies to list on ChiNext, STAR Market, and the Beijing Stock Exchange, to be listed on the New Third Board, and to raise funds through the issuance of corporate credit bonds. It encourages and guides industrial investment funds and venture capital funds to initiate the establishment of sub-funds for the biopharmaceutical industry. It supports eligible biopharmaceutical industrial park projects to issue REITs and real estate trust asset-backed notes in the infrastructure sector.
AASTOCKS Financial News
Website: www.aastocks.com